Login to Your Account

Financings Roundup

Wednesday, March 14, 2012

• Salix Pharmaceuticals Ltd., of Raleigh, N.C., priced an offering of $600 million of 1.5 percent convertible senior notes due March 15, 2019, to institutional buyers and granted the buyers an option to purchase up to an additional $90 million in notes to cover overallotments. The notes are convertible into cash, shares of Salix common stock or a combination of the two, at Salix's election.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription